HFE C282Y Homozygosity Is Associated With Lower Total and Low-Density Lipoprotein Cholesterol The Hemochromatosis and Iron Overload Screening Study

被引:23
作者
Adams, Paul C. [1 ]
Pankow, James S. [2 ]
Barton, James C. [4 ]
Acton, Ron T. [3 ]
Leiendecker-Foster, Cathie [8 ]
McLaren, Gordon D. [5 ,6 ]
Speechley, Mark [7 ]
Eckfeldt, John H. [8 ]
机构
[1] Univ Hosp, Dept Med, London, ON N6A 5A5, Canada
[2] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA
[3] Univ Alabama Birmingham, Dept Microbiol, Birmingham, AL 35294 USA
[4] Univ Alabama Birmingham, So Iron Disorders Ctr, Birmingham, AL 35294 USA
[5] Vet Affairs Long Beach Healthcare Syst, Long Beach, CA USA
[6] Univ Calif Irvine, Div Hematol Oncol, Irvine, CA USA
[7] Univ Western Ontario, Div Epidemiol & Biostat, London, ON, Canada
[8] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA
基金
美国国家卫生研究院;
关键词
hemochromatosis; iron overload; iron; ACUTE MYOCARDIAL-INFARCTION; HEREDITARY HEMOCHROMATOSIS; ATHEROSCLEROSIS RISK; HEART-DISEASE; GENE; MUTATION; CARRIERS; FIBROSIS;
D O I
10.1161/CIRCGENETICS.108.813089
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Previous studies have suggested a positive association of coronary heart disease risk and both serum ferritin concentrations and C282Y heterozygosity. Relationships between serum lipids, C282Y homozygosity, and serum ferritin have not been well established. Methods and Results-The Hemochromatosis and Iron Overload Screening study screened 101 168 participants in primary care from 5 field centers in the United States and Canada with serum ferritin, transferrin saturation, and HFE genotyping for C282Y and H63D mutations. Serum lipids were measured in a subset of 176 C282Y homozygotes (63 male, 113 female whites) without a prior diagnosis of, family history, or treatment for hemochromatosis and a matched sample of participants with normal transferrin saturation and serum ferritin without C282Y or H63D mutations (wild-type, 123 male, 189 female whites). The proportion of subjects who reported using prescription cholesterol-lowering medications was approximate to 3 times higher in HFE wild-type subjects than C282Y homozygotes among men (22% versus 7%; P = 0.02) and, in women, 2 times higher (16% versus 8%; P = 0.07). After excluding subjects taking cholesterol medications, C282Y homozygotes had significantly lower mean total and low-density lipoprotein cholesterol concentrations than wild-type subjects, with larger genotypic differences for low-density lipoprotein in men (-0.62 mmol/L; 95% CI, -0.93 to -0.33) than in women (-0.28 mmol/L; 95%, CI -0.52 to -0.08). Conclusions-Total mean serum cholesterol and low-density lipoprotein levels were lower in C282Y homozygotes than in HFE wild-type participants. Further studies are required to determine whether this is related to iron overload, HFE alleles, or other factors on C282Y-positive chromosome 6p haplotypes. (Circ Cardiovasc Genet. 2009; 2:34-37.)
引用
收藏
页码:34 / 37
页数:4
相关论文
共 24 条
[1]   Liver diseases in the hemochromatosis and iron overload screening study [J].
Adams, Paul C. ;
Passmore, Leah ;
Chakrabarti, Subrata ;
Reboussin, David M. ;
Acton, Ronald T. ;
Barton, James C. ;
Mclaren, Gordon D. ;
Eckfeldt, John H. ;
Dawkins, Fitzroy W. ;
Gordeuk, Victor R. ;
Harris, Emily L. ;
Leiendecker-Foster, Catherine ;
Gossman, Elaine ;
Sholinsky, Phyliss .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2006, 4 (07) :918-923
[2]   Hemochromatosis and iron-overload screening in a racially diverse population [J].
Adams, PC ;
Reboussin, DM ;
Barton, JC ;
McLaren, CE ;
Eckfeldt, JH ;
McLaren, GD ;
Dawkins, FW ;
Acton, RT ;
Harris, EL ;
Gordeuk, VR ;
Leiendecker-Foster, C ;
Speechley, M ;
Snively, BM ;
Holup, JL ;
Thomson, E ;
Sholinsky, P ;
Acton, RT ;
Barton, JC ;
Dixon, D ;
Rivers, CA ;
Tucker, D ;
Ware, JC ;
McLaren, CE ;
McLaren, GD ;
Anton-Culver, H ;
Baca, JA ;
Bent, TC ;
Brunner, LC ;
Dao, MM ;
Jorgensen, KS ;
Kuniyoshi, J ;
Le, HD ;
Masatsugu, MK ;
Meyskens, FL ;
Morohashi, D ;
Nguyen, HP ;
Panagon, SN ;
Phung, C ;
Raymundo, V ;
Ton, T ;
Walker, AP ;
Wenzel, LB ;
Ziogas, A ;
Adams, PC ;
Bloch, E ;
Chakrabarti, S ;
Fleischhauer, A ;
Harrison, H ;
Jia, K ;
Larson, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (17) :1769-1778
[3]  
Armaganijan Dikran, 2003, Rev Port Cardiol, V22, P185
[4]   Haemochromatosis gene mutations and risk of coronary artery disease [J].
Battiloro, E ;
Ombres, D ;
Pascale, E ;
D'Ambrosio, E ;
Verna, R ;
Arca, M .
EUROPEAN JOURNAL OF HUMAN GENETICS, 2000, 8 (05) :389-392
[5]   Longevity and carrying the C282Y mutation for haemochromatosis on the HFE gene:: case control study of 492 French centenarians [J].
Coppin, H ;
Bensaid, M ;
Fruchon, S ;
Borot, N ;
Blanché, H ;
Roth, MP .
BRITISH MEDICAL JOURNAL, 2003, 327 (7407) :132-133
[6]   The origin and spread of the HFE-C282Y haemochromatosis mutation [J].
Distante, S ;
Robson, KJH ;
Graham-Campbell, J ;
Arnaiz-Villena, A ;
Brissot, P ;
Worwood, M .
HUMAN GENETICS, 2004, 115 (04) :269-279
[7]   Hereditary hemochromatosis and risk of ischemic heart disease -: A prospective study and a case-control study [J].
Ellervik, C ;
Tybjærg- Hansen, A ;
Grande, P ;
Appleyard, M ;
Nordestgaard, BG .
CIRCULATION, 2005, 112 (02) :185-193
[8]   Hemochromatosis genotypes and risk of 31 disease endpoints: Meta-analyses including 66,000 cases and 226,000 controls [J].
Ellervik, Christina ;
Birgens, Henrik ;
Tybjaerg-Hansen, Anne ;
Nordestgaard, Borge G. .
HEPATOLOGY, 2007, 46 (04) :1071-1080
[9]   Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model [J].
Forns, X ;
Ampurdanès, S ;
Llovet, JM ;
Aponte, J ;
Quintó, L ;
Martínez-Bauer, E ;
Bruguera, M ;
Sánchez-Tapias, JM ;
Rodés, J .
HEPATOLOGY, 2002, 36 (04) :986-992
[10]  
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499